Unibest
← Back to patent-cliff list

CAS 3536-96-7

Chlorido(ethenyl)magnesium

Codes: (IX)101438-57-a, Atorvastatin-094, Chlorphenamine Maleate-008, (IIa)955428-2-a, Astaxanthin-045

Application context (from source-drug indications)

Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylateCardiac and vascular disordersAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHypertensionAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHyperlipidaemiaAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilHeart diseaseAtorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilNasal congestionDextromethorphan Hydrobromide/Chlorphenamine Maleate/Ammonium chlorideSneezingDextromethorphan Hydrobromide/Chlorphenamine Maleate/Ammonium chlorideCoughDextromethorphan Hydrobromide/Chlorphenamine Maleate/Ammonium chlorideHyperlipidaemiaAtorvastatin strontiumSubarachnoid haemorrhageAtorvastatin strontiumHypertensionAtorvastatin strontiumCommon coldAcetaminophen/Chlorphenamine Maleate/Methylephedrine Hydrochloride/Sulfogaiacol/CaffeineHypersensitivity reactionChlorphenamine MaleateSeasonal allergic rhinitisChlorphenamine MaleateDermatitisChlorphenamine MaleateUrticariaChlorphenamine MaleatePruritusChlorphenamine MaleateDrug eruptionChlorphenamine MaleatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxelPeripheral T-cell lymphomaGolidocitinibEB病毒感染GolidocitinibViral infectionGolidocitinibHistiocytosisGolidocitinib噬血细胞性淋巴组织细胞增多症GolidocitinibInterstitial lung diseaseGolidocitinib营养失调AstaxanthinKnee arthritisAstaxanthinDiabetic neuropathyAstaxanthinStrokeAstaxanthin

Source drugs (routes using this intermediate)

DrugTierExpiry
Paclitaxel/Encequidar mesylateTier C — Watch / trade-
Atorvastatin/Hydrochlorothiazide/Aspirin/EnalaprilTier C — Watch / trade-
Dextromethorphan Hydrobromide/Chlorphenamine Maleate/Ammonium chlorideTier C — Watch / trade-
Atorvastatin strontiumTier C — Watch / trade-
Acetaminophen/Chlorphenamine Maleate/Methylephedrine Hydrochloride/Sulfogaiacol/CaffeineTier C — Watch / trade-
Chlorphenamine MaleateTier C — Watch / trade-
PaclitaxelTier B — Position early-
GolidocitinibTier C — Watch / trade-
AstaxanthinTier C — Watch / trade-

Position in synthesis routes (up/downstream chain)

Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.

Dextromethorphan Hydrobromide/Chlorphenamine Maleate/Ammonium chlorideOptimised routesteps: 3total yield: /
N-Methoxy-N-methylpyridine-2-carboxamide→Chlorido(ethenyl)magnesium→Dimethylamine→3-(Dimethylamino)-1-(pyridin-2-yl)propan-1-one→N,N-Dimethyl-2-([1,2,3]triazolo[1,5-a]pyridin-3-yl)ethan-1-amine→(4-Chlorophenyl)boranediol→1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
N-Methoxy-N-methylpyridine-2-carboxamide→Chlorido(ethenyl)magnesium→Dimethylamine→3-(Dimethylamino)-1-(pyridin-2-yl)propan-1-one→N,N-Dimethyl-2-([1,2,3]triazolo[1,5-a]pyridin-3-yl)ethan-1-amine→(4-Chlorophenyl)boranediol→1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
Chlorphenamine MaleateOptimised routesteps: 3total yield: /
N-Methoxy-N-methylpyridine-2-carboxamide→Chlorido(ethenyl)magnesium→Dimethylamine→3-(Dimethylamino)-1-(pyridin-2-yl)propan-1-one→N,N-Dimethyl-2-([1,2,3]triazolo[1,5-a]pyridin-3-yl)ethan-1-amine→(4-Chlorophenyl)boranediol→1-(p-Chlorophenyl)-1-(2-pyridyl)-3-dimethylaminopropane
GolidocitinibOptimised routesteps: 2total yield: /
(2-Nitrophenyl)boronic acid→Chlorido(ethenyl)magnesium→(Vinyl)magnesium bromide→1H-Indol-7-ylboronic acid→7-Nitro-1H-indole
AstaxanthinOptimised routesteps: 4total yield: /

Intermediates available on this site

No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.

This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.